Literature DB >> 15120669

Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.

Nagi El-Saghir1, Zaher Otrock, Afif Mufarrij, Yasser Abou-Mourad, Ziad Salem, Ali Shamseddine, Jaber Abbas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120669     DOI: 10.1016/S1470-2045(04)01470-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

Review 1.  Overview, prevention and management of chemotherapy extravasation.

Authors:  Firas Y Kreidieh; Hiba A Moukadem; Nagi S El Saghir
Journal:  World J Clin Oncol       Date:  2016-02-10

2.  [Medical emergencies following dermatological injections and infusions].

Authors:  D Dill-Müller
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

Review 3.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Massive breast necrosis after extravasation of a full anthracycline cycle.

Authors:  Ines Vasconcelos; Winfried Schoenegg
Journal:  BMJ Case Rep       Date:  2013-10-18

Review 5.  Treatment of anthracycline extravasations using dexrazoxane.

Authors:  D Conde-Estévez; J Mateu-de Antonio
Journal:  Clin Transl Oncol       Date:  2013-08-15       Impact factor: 3.405

Review 6.  Clinical Applications of Hyaluronidase.

Authors:  Gregor Cornelius Weber; Bettina Alexandra Buhren; Holger Schrumpf; Johannes Wohlrab; Peter Arne Gerber
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

Review 8.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.